Science & Enterprise subscription

Follow us on Twitter

  • Voice telephone, who knew? ... Why the Phone Is Key to Getting Covid Shots in Arms https://t.co/zf0KWGX7Ca
    about 1 hour ago
  • Israel is emerging as the world's leader in vaccinating its population, and seeing results in declines of new Covid… https://t.co/FBswRzZQld
    about 5 hours ago
  • New post on Science and Enterprise: Infographic – Israel Halts Covid-19 Spread with Vaccines https://t.co/ezP927woim #Science #Business
    about 5 hours ago
  • We wrote about this project last July. Read about it first on Science & Enterprise. ... Researchers Are Hatching a… https://t.co/rujRcnlZax
    about 9 hours ago
  • A biotechnology company using protein dynamics to develop precision cancer therapies is acquiring a drug discovery… https://t.co/AzEb3ERy5f
    about 1 day ago

Please share Science & Enterprise

Patent Granted for RNA-Interference to Treat Scar Tissue

RNA illustration

RNA illustration (Research.gov)

5 March 2014. RXi Pharmaceuticals Corp., a biotechnology company in Westborough, Massachusetts, received a patent for its technology based on RNA-interference to treat skin scars, including surgical scars. Patent number 8,664,189 was awarded yesterday by the U.S. Patent and Trademark Office to seven inventors and assigned to RXi Pharmaceuticals.

RXi develops therapies with a technology harnessing RNA, the nucleic acid that sends genetic signals derived from an individual’s DNA to cells with instructions on their functions in the body. The technology uses a specific type of genetic instruction known as RNA-interference, a natural process that regulates the over-expression of proteins from a gene causing a disorder. The company’s therapeutics self-deliver interfering RNA to the affected cells, encouraging cells to take up the RNA, reducing obstacles from immune responses, and providing long-lasting cellular activity.

The patent covers self-delivered RNA-interference addressing connective tissue growth factor, a protein that encourages growth of fibroblasts and collagen, which are useful for healing wounds, but when overproduced, can lead to the formation of scar tissue. The company’s lead product, code-named RXI-109, is an RNA-interference therapy designed to treat surgical scars.

An early-stage clinical trial shows RXI-109 was well-tolerated at multiple dosage levels, and reduced production of connective tissue growth factor in treated areas. Two intermediate-stage clinical trials are now recruiting patients testing RXI-109 against a placebo with surgery to remove keloid scars resulting from earlier surgery or burns, and with abdominal scar revision surgery, following hysterectomy or Cesarean-section delivery.

RXi’s founder is Craig Mello, a professor of molecular medicine at University of Massachusetts medical school in Worcester, who still chairs the company’s scientific advisory board. Mello shares the 2006 Nobel Prize in medicine for his work on RNA-interference. RXI was spun-off from Galena Biopharma in 2012.

Read more:

*     *     *

Comments are closed.